$76.78 Million in Sales Expected for Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) This Quarter

Equities analysts expect Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) to report sales of $76.78 million for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Amphastar Pharmaceuticals’ earnings, with estimates ranging from $72.40 million to $80.40 million. Amphastar Pharmaceuticals reported sales of $75.54 million during the same quarter last year, which would suggest a positive year over year growth rate of 1.6%. The firm is expected to report its next quarterly earnings results on Thursday, November 14th.

On average, analysts expect that Amphastar Pharmaceuticals will report full-year sales of $320.59 million for the current fiscal year, with estimates ranging from $312.50 million to $331.47 million. For the next year, analysts anticipate that the business will post sales of $394.94 million, with estimates ranging from $327.30 million to $458.74 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Wednesday, August 7th. The company reported $0.08 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.03 by $0.05. The company had revenue of $79.00 million for the quarter, compared to the consensus estimate of $78.90 million. Amphastar Pharmaceuticals had a net margin of 16.33% and a return on equity of 5.52%. The firm’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.03 earnings per share.

AMPH has been the topic of several recent research reports. BidaskClub upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday. Wells Fargo & Co set a $29.00 price target on shares of Amphastar Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, June 6th. Zacks Investment Research upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 price target on the stock in a research report on Wednesday, July 10th. Finally, TheStreet upgraded shares of Amphastar Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Amphastar Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $24.64.

Amphastar Pharmaceuticals stock traded down $0.32 during midday trading on Tuesday, reaching $22.24. 222,871 shares of the company traded hands, compared to its average volume of 205,640. The firm has a market capitalization of $1.07 billion, a price-to-earnings ratio of 105.90 and a beta of 1.35. The business has a 50 day moving average of $20.40 and a two-hundred day moving average of $21.31. Amphastar Pharmaceuticals has a 12 month low of $17.71 and a 12 month high of $25.43. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.81 and a quick ratio of 1.83.

In other news, Director Richard K. Prins sold 10,000 shares of the stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $20.78, for a total value of $207,800.00. Following the completion of the sale, the director now directly owns 49,309 shares of the company’s stock, valued at $1,024,641.02. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO William J. Peters sold 4,942 shares of the stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $21.00, for a total transaction of $103,782.00. The disclosure for this sale can be found here. Insiders sold 26,557 shares of company stock worth $549,583 over the last quarter. Insiders own 30.80% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Financial Gravity Wealth Inc. purchased a new stake in shares of Amphastar Pharmaceuticals in the first quarter worth $43,000. Quadrant Capital Group LLC purchased a new stake in shares of Amphastar Pharmaceuticals in the first quarter worth $53,000. Acadian Asset Management LLC purchased a new stake in shares of Amphastar Pharmaceuticals in the second quarter worth $88,000. Bank of Montreal Can increased its stake in shares of Amphastar Pharmaceuticals by 130.7% in the second quarter. Bank of Montreal Can now owns 4,923 shares of the company’s stock worth $104,000 after purchasing an additional 2,789 shares in the last quarter. Finally, Atria Investments LLC purchased a new stake in shares of Amphastar Pharmaceuticals in the second quarter worth $449,000. 48.12% of the stock is owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.

Recommended Story: Stop Order

Get a free copy of the Zacks research report on Amphastar Pharmaceuticals (AMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.